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CONSENSUS
BONE and VIBE data summary
Registration of a new bisphosphonate for the treatment 
of osteoporosis requires fracture data from a randomised, 
placebo-controlled, clinical trial which has fracture reduction 
as its primary outcome. The primary fracture prevention trials 
for the currently available bisphosphonates include:
•  Alendronate (10 mg daily) – The Fracture Intervention 
Trials (FIT 1 & 2) which provided vertebral and 
non-vertebral efficacy data.2,3
•  Risedronate (5 mg daily) – The Vertebral Efficacy with 
Risedronate Therapy (VERT-NA and VERT-International) studies 
which demonstrated vertebral fracture efficacy. The Hip 
Intervention Program (HIP) study demonstrated hip fracture 
reduction with risedronate.4,5
•  Ibandronate (2.5 mg daily) – The Ibandronate Osteoporosis 
Vertebral Fracture Trial in North America and Europe (BONE) 
which demonstrated vertebral fracture efficacy. In a post-hoc 
analysis of non-vertebral fractures, efficacy was demonstrated 
in high-risk patients.6
•  Zoledronate (5 mg IV yearly) – The Health Outcomes and 
Reduced Incidence with Zoledronic acid Once Yearly 
(HORIZON) trial which demonstrated both vertebral and hip 
fracture reduction.7
Ibandronate – The primary fracture prevention trial 
(BONE)
The BONE study is the primary fracture prevention trial for 
oral ibandronate 2.5 mg daily in postmenopausal women 
with osteoporosis and showed a significant (62%) reduction 
in the risk of new vertebral fractures with ibandronate 
2.5 mg daily over the 3-year study duration.6 
The BONE trial was, however, relatively small and did not 
show non-vertebral fracture reduction. 
However, a posthoc analysis in a higher risk subgroup of patients 
(T-score < - 3.0) did show a 69% relative risk reduction in non-
vertebral fractures.6 
Ibandronate – The non-inferiority studies for the longer 
dosing regimens
The European Medicines Agency (EMEA) and the US Food 
and Drug Administration (FDA) suggest that to register 
a different dosing regimen (e.g. weekly or monthly) of a 
bisphosphonate that has previously demonstrated efficacy 
in primary fracture prevention trials, ‘bridging studies’ 
using surrogate endpoints for fracture such as changes in 
BMD have been used.8 In other words, it is not necessary to 
re-evaluate fracture prevention in order to obtain registration 
for a longer dosing regimen. It is accepted that if BMD gains of 
the comparator are non-inferior to the originator (within a pre-
determined range), then fracture efficacy can be expected to be 
similar.
The Monthly Oral Ibandronate in Ladies (MOBILE) Trial was a 
non-inferiority BMD study that compared the efficacy and safety 
of three once-monthly oral ibandronate regimens with the 
ibandronate 2.5 mg daily regimen.9 
Oral ibandronate 150 mg once-monthly provides an 
approximately two-fold increase in the annual cumulative 
exposure to ibandronate compared to the 2.5 mg daily 
formulation.10 The efficacy of this increased dose was examined 
in the pivotal registration study (MOBILE), in which BMD gains 
were significantly greater with 150 mg monthly oral ibandronate 
than with daily ibandronate.10 (See section on MOBILE and 
MOBILE LTE).
Similarly, the Monthly Oral Therapy with Ibandronate for 
Osteoporosis Intervention (MOTION) study which compared 
the efficacy of once-monthly oral ibandronate with weekly 
alendronate in women with postmenopausal osteoporosis 
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showed that the two regimens were comparable at increasing 
BMD after 12 months at both the lumbar spine and total hip.11
Ibandronate – The VIBE database study
No prospective head-to-head trials comparing the antifracture 
efficacy of the currently marketed weekly and monthly 
bisphosphonates have been done, due to the large sample 
size these studies would require to reliably detect differences 
in fracture risk, and the associated high costs.12 For this reason, 
observational database studies are increasingly being used as 
such studies can provide sufficient sample sizes and permit the 
comparison of marketed doses.12 Furthermore, it is unlikely that 
future fracture efficacy trials of bisphosphonate versus placebo 
will be conducted as it would be unethical to randomise patients 
to placebo.
The Evaluation of Ibandronate Efficacy (VIBE) head-to-head 
database fracture study compared fracture rates (hip, non-
vertebral, vertebral and any clinical fracture) adjusted for 
confounding factors, over one year, between patients treated 
with monthly ibandronate 150 mg orally and weekly oral 
bisphosphonates (alendronate, risedronate or a combined 
alendronate/risedronate group).12
The results showed that fracture risk was not significantly 
different between patients receiving monthly ibandronate or 
weekly bisphosphonates for hip, non-vertebral or any clinical 
fracture.12 However, monthly ibandronate-treated patients 
had a significantly lower risk of vertebral fracture than weekly 
bisphosphonate patients.12
In summary, with respect to fracture data:
• Oral daily ibandronate has demonstrated a 62% relative 
risk reduction in new vertebral fractures versus placebo in a 
primary study (i.e. the BONE study).6 
• Monthly ibandronate 150 mg orally has demonstrated a 
significantly lower rate of vertebral fractures versus weekly 
oral bisphosphonates (VIBE study).12
• Monthly ibandronate 150 mg orally has demonstrated 
comparable rates of non-vertebral and hip fractures 
versus weekly bisphosphonates (VIBE study).12 
Non-vertebral and hip fracture IBN = ALN = RIS.
• Monthly oral ibandronate may be considered non-inferior 
with respect to hip fracture compared to the other weekly oral 
bisphosphonates.12
IBN – Ibandronate; ALN – Alendronate; RIS - Risedronate
MOBILE and MOBILE LTE data summary 
(BMD non-inferiority studies)
The MOBILE study was a prospective, randomised, phase lll, non-
inferiority study that compared the efficacy and safety of three 
once-monthly oral ibandronate doses (50+50 mg monthly, given 
on 2 consecutive days; 100 mg monthly; 150 mg monthly) with 
2.5 mg daily ibandronate, which has previously been shown 
to reduce vertebral fracture risk versus placebo. The study was 
conducted in 1609 women aged 55 to 80 years, who were 
at least 5 years postmenopausal and had T-scores between 
< - 2.5 and > - 5.0.9
The primary endpoint of the MOBILE study was the percentage 
change from baseline lumbar spine bone density at one year.
Reginster et al. (2006) discussed the 2-year MOBILE data to 
confirm the one-year results and to provide more extensive 
safety data. Secondary endpoints included the percentage 
change from baseline in lumbar spine and proximal femur BMDs 
over 2 years and the percentage change in serum concentrations 
of the biochemical marker of bone resorption, C-telopeptide of 
the α-chain of type l collagen (sCTX), from baseline over 2 years.9
Substantial increases in lumbar spine BMD were 
seen in all treatment arms. It was confirmed that all 
once-monthly oral ibandronate regimens were at 
least as effective as daily treatment and, in addition, 
150 mg once-monthly was proven to be better at the lumbar 
spine in terms of BMD gains (p < 0.001).9
Substantial increases in proximal femur (total hip, femoral neck, 
trochanter) BMD were also seen, with 150 mg once-monthly 
producing the most pronounced effect (p < 0.05 versus daily 
treatment). Pronounced decreases in sCTX were maintained 
throughout the study.9  Although this study did not assess 
fracture efficacy, the incidence of osteoporotic fractures was 
similar in all treatment groups.
In terms of adverse events, the incidence of upper 
gastrointestinal (GI) adverse events was similar across the 
treatment arms (20 to 26%) and events were generally mild to 
moderate in severity. The incidence of flu-like illness was higher 
with the 150 mg monthly dosing (3.3%) compared with the other 
dosing regimens (0.3% to 1.3%). However, none of the patients 
experiencing flu-like illness during year 1 had a recurrence 
during year 2 and the 2-year results confirm a low incidence of 
flu-like illness with ibandronate, similar to that seen with other 
oral bisphosphonates.9 
Overall, it was concluded that once-monthly oral ibandronate is 
at least as effective and well-tolerated as daily oral treatment. In 
addition, once-monthly administration may be more convenient 
for patients and improve therapeutic adherence, thereby 
optimising outcomes.9 
The long-term efficacy and safety of once-monthly ibandronate 
was studied in the extension to the 2-year MOBILE study, the 
MOBILE-LTE.14 In the long-term extension (LTE), 344 patients 
from MOBILE monthly ibandronate arms and 698 patients 
from all arms were reallocated to ibandronate 100 mg 
monthly or 150 mg monthly for a further 3 years.The primary 
endpoint was the change in mean lumbar spine BMD from 
month 24 to month 60. A secondary efficacy endpoint was 
the change in mean total hip BMD from the end of the 2-year 
MOBILE study (month 24) to completion of the MOBILE-LTE 
at month 60. The primary focus of the study, however, was 
the change in lumbar spine BMD from MOBILE baseline to end 
of 5 years.14
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The 344 patients receiving monthly ibandronate showed 
increases over 5 years in lumbar spine BMD (8.4% with 
150 mg once-monthly) from MOBILE baseline. Total 
hip BMD increased at 12 and 24 months compared to 
MOBILE baseline in both the 150 mg monthly and the 
100 mg monthly treatment groups, but a plateau was reached 
between 24 and 36 months with no further increases. 
Only small changes in BMD were seen at the femoral neck and 
trochanter. Decreases in sCTX and procollagen type 1 amino-
terminal propeptide (P1NP) seen in the 2-year MOBILE results 
were maintained over 5 years.14
In terms of adverse events, the incidence of gastrointestinal 
events in MOBILE LTE was lower than in the MOBILE study (about 
7.4% in each treatment group).14
Joint pain was reported in 4.0% of patients receiving ibandronate 
150 mg. In terms of serious adverse events, there was no evidence 
of renal compromise and there were no symptoms suggestive of 
osteonecrosis of the jaw (ONJ).14
The conclusion of the MOBILE-LTE study was that 150 mg once-
monthly oral ibandronate is an effective and well-tolerated 
treatment for postmenopausal osteoporosis. The BMD at 
the proximal femur is maintained, with further small gains in 
lumbar spine BMD. The efficacy of ibandronate once-monthly is 
sustained over 5 years and there were no new safety signals.14 
Harris meta-analysis  and Cranney pooled analysis 
data summary
Harris meta-analysis 
In the Harris et al. meta-analysis, individual patient data from 
four phase lll (BONE, IV fracture prevention, MOBILE and Dosing 
IntraVenous Administration (DIVA)) studies were grouped into 
three dose levels based on annual cumulative exposure (ACE), 
defined as the annual dose (mg) x bioavailability (0.6% oral; 
100% IV).10 
Non-vertebral and all clinical fractures in postmenopausal 
women over at least 2 years were examined and compared in 
the high-dose ACE group (≥ 10.8 mg), the mid-dose ACE group 
(5.5 to 7.2 mg) and the low-dose ACE group (2.0 to 4.0 mg). Both 
the 150 mg oral once-monthly and the 3 mg IV quarterly fall 
within the high-dose ACE group.10
All four trials had identical procedures for ascertainment of 
non-vertebral fractures (NVFs), including collection of NVFs as 
adverse events and mandatory X-ray confirmation.10
• The BONE and the IV fracture prevention studies were placebo-
controlled 3-year fracture endpoint trials that examined 
vertebral fractures as the primary endpoint. Inclusion criteria 
required 1 to 4 prevalent vertebral fractures, lumbar spine 
BMD and a T-score of -2.0 to -5.0.10
• The MOBILE and DIVA studies were active-controlled 2-year 
BMD studies. Inclusion criteria did not require prevalent 
vertebral fractures, lumbar spine BMD but did require a T-score 
of -2.5 to -5.0.10
Since high ACE ibandronate has been shown to result in larger 
increases in BMD, this study assessed whether these doses would 
also reduce fracture risk relative to placebo.10  
The primary endpoint was key NVFs (clavicle, humerus, 
wrist, hip, pelvis, leg). All NVFs and all clinical fractures 
(a category that includes all NVFs and symptomatic vertebral 
fractures) were also examined.10
All year data showed statistically significant reductions 
in the risk of key non-vertebral fractures, all NVFs and all 
clinical fractures for the high-dose ACE group compared 
with placebo. Reductions in fracture risk for the low- and 
mid-ACE groups compared with placebo did not reach statistical 
significance for most of the fracture types examined. The high-
dose group (ACE ≥ 10.8 mg) also showed a significantly longer 
time to fracture versus placebo for key NVFs, all NVFs and all 
clinical fractures at 2 years.10 
Cranney pooled analysis
The Cranney pooled analysis of ibandronate assessed 
the efficacy of high versus low doses of ibandronate on 
non-vertebral fractures (humerus, clavicle, wrist, pelvis, 
hip and leg). Eight randomised treatment trials were 
considered for inclusion. Treatment trials were defined as 
those trials in which baseline lumbar spine T-score was 
≤ -2.5, or the baseline prevalent vertebral fracture rate was 
> 20%, or the mean age of participants was over 60 years.
Only two trials were selected for inclusion as they provided 
data on prevalent vertebral fractures and data on both 
higher and lower doses of ibandronate.15 
Several doses in addition to the ones used in clinical practice 
were included in the analysis. As in the Harris meta-analysis, the 
annual cumulative exposure (ACE) was used to categorise doses 
as high (≥ 10.8 mg) and low (≤ 7.2 mg).15 
The results showed that combining higher ACE doses of 
≥ 10.8 mg versus ACE doses of 5.5 mg resulted in a 
hazard ratio of 0.62 or a 38% reduction in the incidence 
of non-vertebral fractures (95% CI 0.396-0.974, p=0.038). 
There was also a dose-response effect seen with 
increasing ACE doses (7.2 to 12 mg) compared with ACE of 
5.5 mg, with unadjusted hazard ratios ranging from 0.746 to 
0.573.15 
• An ACE of 12 mg resulted in a 43% reduction in NVF risk 
(95% CI 0.037-1.004)15
• An ACE ≥ 10.8 mg resulted in a 38% reduction in NVF risk 
(95% CI 0.396-0.974)15
• An ACE ≥ 7.2 mg resulted in a non-significant NVF reduction of 
25% (95% CI 0.505-1.103)15
The Kaplan-Meier plot of time to non-vertebral fracture for 
higher versus lower ACE ibandronate doses shows that higher 
doses prolong the time to non-vertebral fractures compared 
with lower doses.15
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In summary, higher doses of ibandronate significantly reduced 
the risk of NVFs in this pooled analysis. However, data on 
prevalent vertebral fracture is not available for all studies, and 
the pooled analysis does not provide enough data in order to 
comment on effect on hip fractures because NVF rate does not 
correlate with hip fracture rate.15
Ibandronate – Long-term data
Ibandronate is a nitrogen-containing bisphosphonate. 
It has an increased potency compared to alendronate 
and risedronate and a higher bone affinity compared to 
clodronate and risedronate.16 Ibandronate offers greater 
ease of use compared weekly with other bisphosphonates. It is 
suitable for both oral and IV administration.16
The long-term safety and efficacy data for the currently 
available bisphosphonates are as follows:
• Alendronate – 10 years, based on the Fracture Intervention 
Trial Extension17
• Risedronate – 7 years, based on the Vertebral Efficacy with 
Risedronate (VERT) trial extension18
• Zoledronate – 9 years, based on the Health Outcomes 
and Reduced Incidence with Zoledronic acid Once Yearly 
(HORIZON) trial extension19
• Ibandronate – 5 years, based on the MOBILE-LTE study14
Efficacy and safety of ibandronate has been 
demonstrated over 5 years14
Observational data over 12 months suggest that ibandronate 
had a significantly lower risk of vertebral fracture than weekly 
bisphosphonate patients (adjusted RR 0.36, 95% CI 0.18-0.75, 
p=0.006)12
Observational data over 12 months suggest that ibandronate 
fracture risk was not significantly different between patients 
receiving monthly ibandronate or weekly bisphosphonates for 
hip, non-vertebral or any clinical fracture (adjusted RR: hip 1.06, 
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